The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Oral tablets.
Anaheim Clinical Trials
Anaheim, California, United States
Time to Maximum Observed Concentration (Tmax) of KAI-7535
Time frame: Pre-dose and up to 60 hours post-dose
Maximum Observed Concentration (Cmax) of KAI-7535
Time frame: Pre-dose and up to 60 hours post-dose
Area Under the Concentration-time Curve From 0 to Time of Last Quantifiable Concentration (AUC0-t) of KAI-7535
Time frame: Pre-dose and up to 60 hours post-dose
Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of KAI-7535
Time frame: Pre-dose and up to 60 hours post-dose
Number of Participants with a Treatment-emergent Adverse Event (TEAE)
Time frame: Day 1 up to Day 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.